SCHEMBL14825415

SCHEMBL14825415

O=C(O)c1ccc(CN2CCC(OC(c3ccccc3)c3ccc(F)cc3)CC2)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 5/20 0.54
▸ GRM5 P41594 1/20 0.46
▸ GRM7 Q14831 1/20 0.46
▸ GRM3 Q14832 1/20 0.46
▸ SLC6A2 P23975 3/20 0.45
▸ DRD3 P35462 2/20 0.45
▸ DRD2 P14416 1/20 0.45
▸ DRD4 P21917 1/20 0.45
▸ SLC6A3 Q01959 4/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ CHRM2 P08172 1/20 0.43
▸ HTR1A P08908 1/20 0.43
▸ ADRA2A P08913 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CHRM1 P11229 1/20 0.43
▸ DRD1 P21728 1/20 0.43
▸ ADRA1A P35348 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14825400 0.95 BCHE (0.50) BCHEGRM5GRM7GRM3SLC6A2
SCHEMBL14825414 0.90 BCHE (0.53) BCHEGRM5GRM7GRM3SLC6A2
SCHEMBL14825442 0.83 BCHE (0.52) BCHESLC6A2DRD3DRD2DRD4
SCHEMBL14825399 0.82 BCHE (0.50) BCHEGRM5GRM7GRM3SLC6A2
SCHEMBL9353208 0.80 BCHE (0.62) BCHEGRM5GRM7GRM3SLC6A2
Hydrochloric Acid SCHEMBL9353408 0.79 BCHE (0.61) BCHEGRM5GRM7GRM3SLC6A2
SCHEMBL14825441 0.79 BCHE (0.52) BCHEGRM5GRM7GRM3SLC6A3
SCHEMBL14825257 0.78 BCHE (0.52) BCHEGRM5GRM7GRM3SLC6A2
Hydrochloric Acid SCHEMBL9352882 0.77 BCHE (0.64) BCHESLC6A2DRD3DRD2DRD4
SCHEMBL14825429 0.77 BCHE (0.52) BCHEGRM5GRM7GRM3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
US-9365553-B2 Heterocyclic compound and H1 receptor antagonist ASKA PHARMACEUTICAL CO., LTD. (JP) 2016-06-14 — — US disclosed
EP-2578569-B1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARM CO LTD (JP) 2015-10-28 — — EP disclosed
EP-2578569-A1 HETEROCYCLIC RING COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA Pharmaceutical Co., Ltd. (JP) 2013-04-10 — — EP disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST ASKA PHARMACEUTICAL CO., LTD (JP) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085127-A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST HRH2, HRH4, HRH1 BCHE 2942/4885GRM5 256/4885GRM7 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback